Therapeutic effect of levosimendan on aged patients with acute heart failure and its influence on cardiac func‐tion ,serum levels of Gal‐3 and CPP／
10.3969/j.issn.1008-0074.2019.01.15
- VernacularTitle:左西孟旦治疗老年急性心力衰竭的疗效及其对心功能、血清 Gal‐3 及 CPP 水平的影响
- Author:
Jinwen LIU
1
;
Zhiguang WU
;
Xiancai YAN
Author Information
1. 广东省中山市中医院急诊科
- Keywords:
Heart failure;
Ventricular function;
Levosimendan;
Aged
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2019;28(1):61-65
- CountryChina
- Language:Chinese
-
Abstract:
Objective :To study therapeutic effect of levosimendan on aged patients with acute decompensated heart failure (ADHF) and its influence on cardiac function ,serum levels of galectin‐3 (Gal‐3) and copeptin (CPP).Methods :A total of 96 aged ADHF patients ,who were treated in our hospital from Jan 2014 to May 2017 ,were selected .Patients were ran‐domly and equally divided into routine treatment group and levosimendan group (received levosimendan based on routine treatment group) ,both groups were treated for 7d.HRV indexes :SDANN ,SDNN ,SDNNI ,PNN50 ,rMSSD ,LF ,HF , LVEDd ,LVEF ,transmitral early diastolic peak flow velocity／late diastolic peak flow velocity (E／A) ,serum levels of Gal‐3 and CPP before and after treatment ,and incidence of adverse reactions were observed and compared between two groups . Results :Compared with before treatment ,after treatment ,there were significant rise in SDANN ,SDNN ,SDNNI ,PNN50 , rMSSD ,LF ,HF ,LVEF and E／A ,and significant reductions in LVEDd ,serum levels of Gal‐3 and CPP in two groups ,P＜0.01 all.Compared with routine treatment group after treatment ,there were significant rise in SDANN [(63.65 ± 6.38) ms vs.(91.32 ± 9.15)ms] ,SDNN[(89.75 ± 9.04)ms vs.(118.65 ± 12.85)ms] ,SDNNI [(37.86 ± 3.81)ms vs.(45.32 ± 4.62)ms] ,PNN50[(5.15 ± 0.52 )% vs.(5.42 ± 0.58 )%] , rMSSD [(31.98 ± 3.31 )ms vs.(37.44 ± 3.77 )ms] , LF [(189.87 ± 19.92)ms2 vs.(223.85 ± 22.57)ms2 ] ,HF [(79.93 ± 8.22) ms2 vs.(94.12 ± 9.53)ms2 ] ,LVEF [(47.38 ± 4.75)% vs.(52.84 ± 5.31)%]and E／A[(0.98 ± 0.26) vs.(1.38 ± 0.31)] ,and significant reductions in serum levels of Gal‐3[(28.69 ± 2.93)ng／L vs.(16.37 ± 1.65)ng／L]and CPP[(1.50 ± 0.16)μg／L vs.(0.93 ± 0.11)μg／L]in levosimendan group , P＜0.05 or ＜0.01. There was no significant difference in incidence rate of adverse reactions during treatment be‐tween two groups , P＝0.473. Conclusion :Levosimendan can effectively reduce serum levels of Gal‐3 and CPP ,improve HRV and cardiac function with good safety in ADHF patients ,which is worth extending .
